Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression

J J Maller; Kathryn Broadhouse; A J Rush; E Gordon; S Koslow; S M Grieve

doi:10.1038/mp.2017.224

Back

Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression

Journal article

Peer reviewed

Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression

J J Maller, Kathryn Broadhouse, A J Rush, E Gordon, S Koslow and S M Grieve

Molecular Psychiatry, Vol.23(8), pp.1737-1744

2018

DOI: https://doi.org/10.1038/mp.2017.224

Files and links (1)

url

https://doi.org/10.1038/mp.2017.224View

Published Version

Abstract

antidepressant agent

escitalopram

sertraline

venlafaxine

Studies of patients with major depressive disorder (MDD) have consistently reported reduced hippocampal volumes; however, the exact pattern of these volume changes in specific anatomical subfields and their functional significance is unclear. We sought to clarify the relationship between hippocampal tail volumes and (i) a diagnosis of MDD, and (ii) clinical remission to anti-depressant medications (ADMs). Outpatients with nonpsychotic MDD (n=202) based on DSM-IV criteria and a 17-item Hamilton Rating Scale for Depression (HRSD17) score ⩾16 underwent pretreatment magnetic resonance imaging as part of the international Study to Predict Optimized Treatment for Depression (iSPOT-D). Gender-matched healthy controls (n=68) also underwent MRI scanning. An automated pipeline was used to objectively measure hippocampal subfield and whole brain volumes. Remission was defined as an HRSD17 of ⩽7 following 8 weeks of randomized open-label treatment ADMs: escitalopram, sertraline or venlafaxine-extended release. After controlling for age and total brain volume, hippocampal tail volume was larger in the MDD cohort compared to control subjects. Larger hippocampal tail volume was positively related to clinical remission, independent of total hippocampal volume, total brain volume and age. These data provide convergent evidence of the importance of the hippocampus in the development or treatment of MDD. Hippocampal tail volume is proposed as a potentially useful biomarker of sensitivity to ADM treatment.

Details

Title: Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression
Authors: J J Maller (Author) - University of Sydney
Kathryn Broadhouse (Author) - University of Sydney
A J Rush (Author) - Duke-National University of Singapore, Singapore
E Gordon (Author) - Brain Resource Ltd, Sydney
S Koslow (Author) - University of Miami, United States
S M Grieve (Author) - University of Sydney
Publication details: Molecular Psychiatry, Vol.23(8), pp.1737-1744
Publisher: Nature Publishing Group
Date published: 2018
DOI: 10.1038/mp.2017.224
ISSN: 1359-4184
Organisation Unit: School of Science and Engineering - Legacy; School of Health - Nursing; University of the Sunshine Coast, Queensland; School of Health and Sport Sciences - Legacy
Language: English
Record Identifier: 99450765802621
Output Type: Journal article

Metrics

92 Record Views

73 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Industry collaboration; Domestic collaboration; International collaboration
Web Of Science research areas: Biochemistry & Molecular Biology; Neurosciences; Psychiatry

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites